Inflammation

Xigen’s lead compound, XG-102, is a highly selective, non-ATP competitive inhibitor of c-jun N-terminal kinase (JNK), a therapeutic target considered a pivotal player in the development of many diseases and conditions with unmet medical needs and proven commercial value. XG-102 has demonstrated superior efficacy to industry recognised benchmarks in a battery of preclinical models for major inflammatory indications. XG-102 is rapidly cleared from the plasma but remains metabolically stable in target cells. It shows an excellent safety and toxicology profile, with no immunogenicity in animals.

In 2009, Xigen completed an exploratory Phase I clinical trial on XG-102, the first time it had been administered intravenously in humans. The placebo-controlled study involved ten patients who had sustained either a stroke or a transient ischemic attack (TIA). The treatment was well tolerated, with no adverse events reported related to the treatment.

Xigen is proceeding with further clinical studies on XG-102 to demonstrate efficacy following systemic administration, including the testing of multiple doses and the measurement of a broad range of biomarkers ex vivo – a prerequisite for addressing important inflammatory conditions. Xigen is actively seeking industry partners for XG-102, as well as for several other promising peptide drug candidates in its growing product pipeline.

Xigen has developed a second generation JNK inhibitor that functions like XG-102 but has been engineered to have different metabolic properties, opening new perspectives for this product in the field of inflammation.

XG-2xx, is a kinase inhibitor for use and inflammation.